Aarey Drugs Q1 FY27 Unaudited Results: Income ₹46.34 Crore, Net Profit ₹1.02 Crore
Aarey Drugs & Pharmaceuticals Limited reported unaudited financial results for Q1 FY27. Total income from operations was ₹46.34 crore. Net profit after tax stood at ₹1.02 crore. Basic and diluted EPS were ₹0.36. The Board approved the results on August 14, 2026.
The financial results are routine and do not contain any significant new information or strategic changes that would materially impact the company's stock price or market position.
The financial results for the quarter are largely in line with expectations, with no significant positive or negative surprises. The net profit shows a marginal increase compared to the previous year's quarter, but the income has decreased.
Aarey Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the quarter and three months ended June 30, 2026. The company reported a total income from operations of ₹46.34 crore for the quarter. The net profit after tax and exceptional items stood at ₹1.02 crore.
For the same period, the net profit before tax and exceptional items was ₹51.56 lakh. The total comprehensive income for the period, comprising profit for the period after tax and other comprehensive income, was ₹102.37 lakh.
The company's paid-up equity share capital remained ₹28.45 crore. Basic and diluted earnings per share (EPS) before extraordinary items were ₹0.36, and after extraordinary items, they were also ₹0.36.
The Board of Directors approved these results at a meeting held on August 14, 2026. The statutory auditors have carried out a limited review. These results were published in 'News Hub' (English and Marathi editions) on August 15, 2026, and have also been uploaded on the company's website.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.